Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access
Official Title: A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA
Brief Summary:
The Expanded Access Program (EAP) is an open-label, multicenter program to:
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.